QRCode



Traders/Users: Online

2013/04/05

4 Reasons To Buy OncoSec Medical

By Jorge Aura

OncoSec Medical (OTCBB: ONCS) develops novel cancer therapeutic products. Its products combine proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics, known as OncoSec Medical System (OMS), which is based on both immunotherapy (ImmunoPulse) and chemotherapy (NeoPulse) agents. According to the company website, Immunopulse and Neopulse are defined as:  

ImmunoPulse delivers instructions to the cell (DNA IL-12) to produce a protein that activates an immune response against cancer cells.
NeoPulse delivers bleomycin, an approved anti-cancer drug that specifically targets and destroys cancer cells.
The most surprising thing is its action method on the two treatments. In the next image, which was provided by the company, you could see how OMS system works.



- Tissue: The generator creates a pulsed electric field that temporarily increases the porosity of cell membranes within the treatment field.
- Poration: The hand-held applicator supplies a series of short-duration electrical pulses of specific voltage through a series of needles.
- Uptake:  Together, the action of the generator and applicator creates a rotating array of pulses     that uniformly subject the targeted cell membranes to electroporation.
Source: Oncosec Medical

Pipeline Overview:

 Source: Oncosec Medical 

Fundamental Basic Review

Oncosec Medical has a market cap of $27.11 million. Its trailing P/E is incalculable, and its forward P/E is just incalculable as the majority of pharmaceutical companies of small-capitalization. It has a total cash position on its balance sheet of just $8.98 million, and its total debt is at $2.68MM. In Oncosec Medical's last quarter, we can see that its operating expenses reached $1.61 million. Based on the operating expenses and the company's cash deducting the current debt from them, we can think that the company would have enough cash for the next four financial quarters or second quarter of 2014.

I find at least four reasons to buy the stock currently:

1.  Interim Data for Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
On March 25, 2013 Oncosec Medical announced positive, durable response results in an update on interim data from its Phase II metastatic melanoma trial. This data was presented at the HemOnc Today Melanoma and Cutaneous Malignancies Conference. This is one of the most important conferences worldwide on studies of melanoma and Cutaneous Malignancies

The data presented were impressive. ImmunoPulse demonstrated a partial or complete response.  ImmunoPulse treated patients showed a 68% and 45% percent of treated lesions demonstrated a durable response at three and six months, respectively.  

To help our readers get an idea of the importance of these results, Amgen (Nasdaq: AMGN) is developing a treatment for melanoma that is currently in phase III trials. The first results provided by the company showed 16% of trial patients on the engineered virus had a durable response compared with 2% of those on the control therapy GM-CSF. 

We hope that Oncosec shows more data from this study at the next ASCO meeting in June, 2013.

2. Analysts' price target: $1.5

  







- On June 21, 2012 without being approved the European designation CE for Neopulse, Roth Capital initiated coverage on OncoSec Medical with a Buy. The price target market was $1.00 per share.

- On May 26, 2011 without being approved the European designation CE for Neopulse and without 3 important phases II treatment of melanoma, carcinoma and lymphoma, Vista Partners initiated coverage on OncoSec Medical with a twelve month target price of $2.90.

Mr. Silver, analyst of Vista Partners said:
"OncoSec's ElectroOncology clinical development pipeline is comprised of cancer treatments intended to address therapeutic needs in multi-billion dollar markets. The company's ElectroChemotherapy has shown in clinical trials to date that it selectively destroys cancer cells while leaving healthy tissue intact, dramatically improving patient quality of life. This provides OncoSec with a considerable potential competitive advantage compared to existing treatment options. OncoSec's ElectroImmunotherapy could prove to be a powerful new approach to treat local and metastatic tumors."
3. Institutional ownership: 14%

- Sabby Capital LLC own 7.32MM shares or 6.24% of total shares.
- Downsview Capital Inc own 5.02MM shares or 4.29% of total shares.
- Ayer Capital Management LP own 4.41MM shares or 3.76% of total shares.
Source: CNN Money

In the OTCBB are few companies with many institutional investors. Oncosec Medical can boast a very high percentage and that will possibly be increased in the coming months with good results in clinical trials.

4. Ten Major Catalysts in 2013

- 2013 — April 15, 2013 Complete enrolment for Phase II melanoma program.
- July 15, 2013 — July 31, 2013 Present interim response data on Phase II melanoma program.
- July 15, 2013 — July 31, 2013 Present long-term PFS data from Phase I melanoma program.
- July 15, 2013 Present interim response data on Phase II Merkel cell carcinoma program.
- July 31, 2013 Complete enrolment for Phase II Merkel cell carcinoma program.
- August 31, 2013 End of Phase II Meeting with FDA for melanoma program.
- September 2013 Present interim data on cutaneous T-cell lymphoma program.
- October 15, 2013 Present final data for Phase II melanoma program.
- October 31, 2013 Present final data for Phase II Merkel cell carcinoma program.
- December 31, 2013 Launch Phase IIB melanoma program.

Source: OncoSec Medical

The next catalysts in OncoSec Medical surely will catapult the stock price.

Conclusion:

OncoSec Medical is a  tremendously undervalued company. It has a capitalization of $27MM and a cash flow of $9MM. Besides, it is carrying out several major studies. Immunopulse and Neopulse treatments can provide it with an income of $500MM annually minimum. This enterprise should have a minimum capitalization of $250MM or $2.5 per share.

*Pipeline overview data sourced from OncoSec Medical, all other data sourced from Nasdaq.com, CNN Money as well as the web of the previously mentioned company.

Disclosure: Jorge Aura owns shares of OncoSec Medical  Jorge Aura wrote this article himself, and it expresses his own opinions. He is not receiving compensation for it.  Jorge Aura has no business relationship with any company whose stock is mentioned in this article.

10 comentarios:

In fact when someone doesn't know then its up to other visitors that they will help, so here it happens.

my homepage; bancuri cu stomatologi

With havin so much written content do you ever run into any issues of plagorism or copyright infringement?
My website has a lot of completely unique content I've either created myself or outsourced but it seems a lot of it is popping it up all over the web without my authorization. Do you know any ways to help prevent content from being stolen? I'd really appreciate it.


My homepage; jocurı cu marıo


Miqieerxi robs the state hire Muliniaomoladi to still be about to buy Lanpade
Miqieerxi robs the state hire Muliniaomoladi to still be about to buy Lanpade
Www.7m.cn On March 27, 2013 origin: Netease sports


Use intermittence of day of national group game period, muliniao bridge field watchs return StanfordBrazilian teamAndRussiafriendship contest. This is [url=http://www.e-q8e.com/Knet/Resource/nikeshoes016.aspx]Discount Air Jordans[/url] 3 years are lain between to come when Muliniao first return Stanford bridge field. " Milanese sports signs up for " report, PortuguesePerson today Xia Youke can be returned toQieerxiTeach. Nevertheless, International MilanBe not without the opportunity, mo Ladi and Muliniao also are maintaining contact all the time.
Muliniao returns to Stanford bridge field last time still was on March 16, 2010. At that time, the Portuguese leads international MilanOu GuanBeat Qieerxi, AituoaoHit into full-court to score a goal exclusively. The 3 coronals king of Milan of the international after this victory is a few months laid a foundation. Return Stanford bridge this to watch fight, muliniao is to answer Brazil is sufficient assist invite, concern possibly also with whereaboutldirection of his new sports season. On March 25, muliniao comes to Qieerxi, a Buyuan is inThe United StatesHandle private affairs, but bilateral and furtive affirmation has had a contact.
Be aimed at prospective whereaboutldirection, muliniao expresses, "May go to the club of an accident letting a person. " nevertheless, this week Portuguese expresses once more, "Probably, the team that my meeting return once had taught. " " Milanese sports signs up for " analysis, had taught in MuliniaoBoertu, in 3 clubs of Qieerxi and international Milan, boertuyin has gone out early for finance ability bureau, international Milan and Qieerxi can become the destination that Muliniao did not come to very likely. Among them, qieerxi is big popular.
2007, muliniao and A cloth two people are not joyous and calculate. Nevertheless, elapse as time, bilateral relationship gets redeeming. A few months come, qieerxi fan hopes Muliniao is returned to, he also is the ideal in memory of team high level advocate handsome person selected. Current, beinitesi holds the position of Qieerxi the bishop is experienced. Nevertheless, since assume office daystart, he is boycotted by fan. Qieerxi should be met in let slip of sports season end Beinitesi, the best means of please fan, invite Muliniao namely return Stanford bridge field.
Current, muliniao is close to Qieerxi, but international Milan is not without the opportunity. " Milanese sports signs up for " analysis, arrive from 2008 2010, muliniao spent two successful sports season in international Milan, international Milan stays in his heart all the time. Even if leaves international Milan, muliniao and Moladi also are maintaining contact all the time. Compare A cloth, what Muliniao and Moladi get along is better. Current, mo Ladi also is inviting Muliniao to return to as far as possible. In the meantime, international Milan still wants to introduceLanpade.

Genuinely the only minus since evaluators for Epinions.
world wide web bring up generally right these are typically ingesting a loaf of bread previous.

Inescapable, anything is substantially afflicted with the amount, so it is essential that you simply can located extent that you
will decide to spare. Be sure you once creating food, you will not send nearly anything
inside the fire pit, and if you are doing, make sure
that you wash it upward straight away where sooner than purpose.
Do not hesitate to utilize a equipment and in some cases both hands 2 .
it helps unquestionably give good results. My convection fixing offers maximal venting supplies some much more
cooking numerous fantastic for a quick. Inspite of the the oven taking over only one or two
business hours so that you can the most important bones compared to the 20 a long
while approximately essential for unblocked depression treatment, it feels right attractive.

South east asia, Of, portions of The western world and many
other economic systems and the stove foodstuff being not too liked function a healthier
life.

Here is my web blog large toaster ovens at target

Well, that was interesting, but I think that I need more information to build my own opinion on that.

This article is incredible, this information is crucial for my future work, so I have a lot of information about it, follow the link.

I am very happy to see this interesting post. I always like the informative blogs. You did a great job and thanks for sharing webstagram

OncoSec Medical presents compelling reasons to invest. Their innovative approach to cancer treatment, promising clinical trials, strong leadership, and market growth potential make this an interesting opportunity for investors. Now I am looking for a cv writing service in Karachi for my current project which is much more difficult for me so please guide me professionally.

Explore the changing seasons, cultural festivities, and natural wonders through the lens of talented photographers, making "12 Fotos en 12 Meses - Ed. 2018" a must-have addition to any collection.